Vanguard Group Inc Neurocrine Biosciences Inc Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
642Shares Held
94.9MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.14 Billion0.04% of portfolio
-
State Street Corp Boston, MA5.15MShares$775 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$387 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$281 Million3.62% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$280 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...